Related Experiment Video
Updated: Mar 14, 2026

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
Published on: May 16, 2025
EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other
R Agca1, S C Heslinga1, S Rollefstad2
1Departments of Rheumatology, Amsterdam Rheumatology and Immunology Center, Reade & VU University Medical Center, Amsterdam, The Netherlands.
Insights
Patients with inflammatory joint disorders (IJD) face higher cardiovascular disease (CVD) risks. Updated European guidelines now emphasize rheumatologist-led CVD risk management in IJD patients, incorporating new evidence and recommendations.
Area of Science:
- Rheumatology
- Cardiology
- Public Health
Background:
- Patients with rheumatoid arthritis (RA) and other inflammatory joint disorders (IJD) exhibit elevated cardiovascular disease (CVD) risk compared to the general population.
- Previous 2009 European League Against Rheumatism (EULAR) recommendations for CVD risk management in IJD were primarily based on expert opinion.
Framework:
- An updated EULAR taskforce, comprising a multidisciplinary committee from 13 European countries, systematically reviewed new evidence to revise CVD risk management recommendations for IJD.
- Three core principles guide the update: heightened CVD risk in RA and potentially other IJD, rheumatologist responsibility for CVD risk management, and judicious use of NSAIDs and corticosteroids.
Implementation:
- Ten revised recommendations were established, including one novel recommendation and modifications to six existing ones from the 2009 guidelines.
- Evidence supporting each recommendation was categorized, reflecting a consensus-driven process involving patient representatives, rheumatologists, cardiologists, and other experts.
Implications:
- The updated recommendations reinforce the increased CVD risk across the spectrum of IJD, underscoring the critical need for proactive CVD risk management.
- These guidelines provide evidence-based and expert-informed assistance for managing cardiovascular risk in patients with inflammatory joint disorders.
Abstract:
Patients with rheumatoid arthritis (RA) and other inflammatory joint disorders (IJD) have increased cardiovascular disease (CVD) risk compared with the general population. In 2009, the European League Against Rheumatism (EULAR) taskforce recommended screening, identification of CVD risk factors and CVD risk management largely based on expert opinion. In view of substantial new evidence, an update was conducted with the aim of producing CVD risk management recommendations for patients with IJD that now incorporates an increasing evidence base. A multidisciplinary steering committee (representing 13 European countries) comprised 26 members including patient representatives, rheumatologists, cardiologists, internists, epidemiologists, a health professional and fellows. Systematic literature searches were performed and evidence was categorised according to standard guidelines. The evidence was discussed and summarised by the experts in the course of a consensus finding and voting process. Three overarching principles were defined. First, there is a higher risk for CVD in patients with RA, and this may also apply to ankylosing spondylitis and psoriatic arthritis. Second, the rheumatologist is responsible for CVD risk management in patients with IJD. Third, the use of non-steroidal anti-inflammatory drugs and corticosteroids should be in accordance with treatment-specific recommendations from EULAR and Assessment of Spondyloarthritis International Society. Ten recommendations were defined, of which one is new and six were changed compared with the 2009 recommendations. Each designated an appropriate evidence support level. The present update extends on the evidence that CVD risk in the whole spectrum of IJD is increased. This underscores the need for CVD risk management in these patients. These recommendations are defined to provide assistance in CVD risk management in IJD, based on expert opinion and scientific evidence.
Related Concept Videos
Rheumatic Heart Disease III: Medical Management
Rheumatic Heart Disease IV: Nursing Management
Atherosclerosis III: Management
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Rheumatic Heart Disease I: Introduction
Myocarditis III: Medical Management

